RedHill Biopharma Ltd. RDHL

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —$8.0M$6.5M$61.8M$85.8M$64.4M$6.3M$8.4M$4.0M$101.0K
Operating income —-$14.6M$12.6M-$42.8M-$81.1M-$63.7M-$43.2M-$39.3M-$52.0M-$30.5M
Net income —-$8.3M$23.9M-$71.7M-$97.7M-$76.2M-$42.3M-$38.8M-$45.5M-$29.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets —$18.0M$23.0M$158.9M$181.2M$180.2M$74.1M$62.4M$57.3M$74.2M
Total equity —-$4.7M$2.1M-$48.4M$8.9M$13.9M$60.0M$51.2M$45.1M$62.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-049055.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
  • Total assets
Revenue, Gross profit, Net income, Total assets by fiscal year, in US dollars The same figures are in the table below this chart. -100M 0 100M 200M Revenue, FY2016: 101K Net income, FY2016: -29.4M Total assets, FY2016: 74.2M Revenue, FY2017: 4M Net income, FY2017: -45.5M Total assets, FY2017: 57.3M Revenue, FY2018: 8.4M Net income, FY2018: -38.8M Total assets, FY2018: 62.4M Revenue, FY2019: 6.3M Net income, FY2019: -42.3M Total assets, FY2019: 74.1M Revenue, FY2020: 64.4M Net income, FY2020: -76.2M Total assets, FY2020: 180.2M Revenue, FY2021: 85.8M Net income, FY2021: -97.7M Total assets, FY2021: 181.2M Revenue, FY2022: 61.8M Net income, FY2022: -71.7M Total assets, FY2022: 158.9M Revenue, FY2023: 6.5M Net income, FY2023: 23.9M Total assets, FY2023: 23M Revenue, FY2024: 8M Net income, FY2024: -8.3M Total assets, FY2024: 18M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $101.0K $4.0M $8.4M $6.3M $64.4M $85.8M $61.8M $6.5M $8.0M —
Gross profit — — — — — — — — — —
Net income -$29.4M -$45.5M -$38.8M -$42.3M -$76.2M -$97.7M -$71.7M $23.9M -$8.3M —
Total assets $74.2M $57.3M $62.4M $74.1M $180.2M $181.2M $158.9M $23.0M $18.0M —

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
AKTX Akari Therapeutics Plc $1.79T — —
LLY ELI LILLY & Co $1.08T 50.1x 44.7%
JNJ JOHNSON & JOHNSON $663.28B 25.0x 6.0%
ONC BeOne Medicines Ltd. $529.55B 1,885.6x 40.2%
ABBV AbbVie Inc. $453.19B 108.7x 8.6%
MRK Merck & Co., Inc. $370.89B 20.6x 1.3%
ABT ABBOTT LABORATORIES $188.69B 29.1x 5.7%
PFE PFIZER INC $162.16B 20.9x -1.6%